OmniAb Inc (NASDAQ:OABI), a biotechnology platform company, reported its fourth quarter and full-year 2025 financial results, delivering revenue and earnings that fell short of Wall Street expectations. The company's shares showed muted initial reaction in after-hours trading following the release.
Earnings and Revenue Versus Estimates
The company's financial performance for the final quarter of 2025 came in below analyst consensus estimates. Revenue declined year-over-year, reflecting a shift in the company's revenue mix as it transitions its business model.
- Q4 2025 Revenue: Reported at $8.4 million, missing the analyst estimate of approximately $9.2 million.
- Q4 2025 EPS: Reported a net loss per share of ($0.11), which was wider than the estimated loss of ($0.09).
For the full year 2025, total revenue was $18.7 million, down from $26.4 million in 2024. The company attributed the decline primarily to decreases in license and milestone revenue, as well as service revenue from completed or discontinued legacy small molecule ion channel programs. This was partially offset by new revenue from its xPloration partner access program.
Market Reaction and Financial Outlook
The immediate market reaction was neutral in after-hours trading, suggesting investors had anticipated a challenging quarter or are focusing more intently on the company's forward guidance and pipeline progress. OmniAb provided financial guidance for 2026, projecting revenue in the range of $25 million to $30 million. This outlook sits below the current analyst sales estimate of $32.6 million for the full year 2026, which may temper near-term growth expectations.
The company also expects its net loss to continue, with cash costs and operating expenses projected between $50 million and $55 million. OmniAb ended 2025 with $54.0 million in cash, cash equivalents, and short-term investments, and anticipates ending 2026 with between $30 million and $35 million in cash.
Key Business Highlights and Operational Progress
Beyond the financials, management emphasized operational milestones and an expanding partner base. CEO Matt Foehr highlighted the company's disciplined cost structure and a growing portfolio of partner programs as key strengths.
- Partner and Program Growth: OmniAb exited the year with 107 active partners and 407 active programs, including 32 OmniAb-derived programs in clinical development or being commercialized.
- Technology Launch: The company recently launched OmniUltra™, a transgenic chicken platform designed to generate ultralong CDRH3 domains and picobodies, which it believes will attract new partners for complex therapeutic applications like bispecifics and CAR-T therapies.
- Partner Pipeline Updates: The press release noted several upcoming clinical milestones from partners, including topline data expected in 2026 from Immunovant's Phase 3 studies for thyroid eye disease and Phase 2a data from Teva Pharmaceuticals for celiac disease.
Conclusion
OmniAb's fourth-quarter results reflect the inherent volatility of a platform biotechnology company's revenue, which is tied to discrete partner licensing events and milestone achievements. While the top and bottom-line misses and a conservative 2026 revenue outlook may give investors pause, the company is pointing to its expanding partner network, innovative technology launches like OmniUltra, and the advancement of late-stage partner assets as the foundation for future milestone and royalty revenue. The market's initial subdued reaction indicates a wait-and-see approach, with focus likely shifting to the execution of its 2026 guidance and the progression of its partners' clinical trials.
For a detailed look at OmniAb's historical earnings, future estimates, and analyst projections, visit the earnings and estimates page.
Disclaimer: This article is for informational purposes only and does not constitute investment advice, financial analysis, or a recommendation to buy or sell any security. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.
